دورية أكاديمية
أعرض في EDS

The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002-2021): a population-based study.

التفاصيل البيبلوغرافية
العنوان: The trends in lung cancer prevalence, incidence, and survival in Hong Kong over the past two decades (2002-2021): a population-based study.
المؤلفون: Au PC; Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-56, 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China., Lee AW; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China., Lee VH; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China., Wong IC; Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-56, 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.; Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Pak Shek Kok, Hong Kong SAR, China.; Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.; Aston Pharmacy School, College of Health and Life Sciences, Aston University, Birmingham, UK., Hui RY; Centre of Cancer Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China., Cheung CL; Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-56, 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.; Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Pak Shek Kok, Hong Kong SAR, China.
المصدر: The Lancet regional health. Western Pacific [Lancet Reg Health West Pac] 2024 Feb 16; Vol. 45, pp. 101030. Date of Electronic Publication: 2024 Feb 16 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101774968 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-6065 (Electronic) Linking ISSN: 26666065 NLM ISO Abbreviation: Lancet Reg Health West Pac Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Elsevier Ltd., [2020]-
مستخلص: Background: Over the past decades, significant progress in lung cancer management has been made. However, the trends in prevalence and survival of lung cancer in the Chinese population over the last decade remain unexplored. This study utilised a territory-wide electronic medical database in Hong Kong to provide the most up-to-date and comprehensive analysis of the trends in prevalence, incidence, and survival over the past two decades.
Methods: Descriptive epidemiology study using a retrospective cohort of lung cancer patients from the Clinical Data Analysis and Reporting System (CDARS). 10-year limited-duration prevalence, incidence, and relative period survival were calculated between 2002 and 2021. Sub-groups of age, sex, and comorbidity were examined. The annual percent change (APC) and average annual percent change (AAPC) were estimated using joinpoint regression.
Findings: This study included 87,259 incident cases between 2002 and 2021. The 10-year limited duration prevalence (per 100,000 persons) of lung cancer increased from 153.4 to 228.7 (AAPC: 3.08%). Crude incidence (per 100,000 persons) increased from 55.0 to 70.3 (APC: 1.23%), while age-standardised incidence decreased from 42.9 to 33.2 (APC: -1.32%). The 1-year and 5-year relative period survivals showed an increasing trend but remained low. Disparity in trends was observed among different sex and age groups.
Interpretation: Lung cancer burden has been increasing partly due to population ageing. Although survival showed improvement over the years, it remained low, highlighting the potential need for interventions. Further study exploring the disparity in sex-specific trends is warranted.
Funding: The Innovation and Technology Commission, Hong Kong.
Competing Interests: PCA, AWL, VHL, ICW, and CLC declare that they have no competing interests. RYH declares that in the past 36 months, all outside of the submitted work, the author received grants from AstraZeneca, Bristol Myers Squibb, Corvus, Eisai, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, and Roche; consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, Merck Sereno, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Takeda, and Zai Lab; honoraria from AstraZeneca, Eli Lilly, Janssen, Merck Sharp & Dohme, and Novartis. The study sponsor, ITC, did not interfere with authors’ access to study’s data, or that interfere with their ability to analyse and interpret the data and to prepare and publish manuscripts independently.
(© 2024 The Author(s).)
References: J Clin Oncol. 2017 Jun 20;35(18):2053-2061. (PMID: 28471724)
N Engl J Med. 2020 Aug 13;383(7):640-649. (PMID: 32786189)
Zhongguo Fei Ai Za Zhi. 2023 Jan 20;26(1):1-9. (PMID: 36792074)
JAMA. 2002 Mar 6;287(9):1132-41. (PMID: 11879110)
J Thorac Oncol. 2022 Feb;17(2):186-193. (PMID: 35074225)
JAMA. 2021 Mar 09;325(10):962-970. (PMID: 33687470)
N Engl J Med. 2020 Feb 6;382(6):503-513. (PMID: 31995683)
Ann Oncol. 2009 Apr;20(4):746-51. (PMID: 19150939)
Med Care. 2005 Nov;43(11):1130-9. (PMID: 16224307)
Biometrics. 1999 Dec;55(4):1137-44. (PMID: 11315059)
Ann Am Thorac Soc. 2017 Oct;14(10):1571-1580. (PMID: 28541748)
Sci Total Environ. 2017 Feb 1;579:1460-1466. (PMID: 27913022)
Lancet Glob Health. 2018 May;6(5):e555-e567. (PMID: 29653628)
MMWR Morb Mortal Wkly Rep. 2018 Nov 09;67(44):1225-1232. (PMID: 30408019)
Ann Am Thorac Soc. 2016 Jan;13(1):58-66. (PMID: 26730864)
Methods Inf Med. 2009;48(2):123-8. (PMID: 19283308)
N Engl J Med. 2009 Sep 3;361(10):947-57. (PMID: 19692680)
N Engl J Med. 2011 Aug 4;365(5):395-409. (PMID: 21714641)
Lung Cancer. 2003 May;40(2):131-40. (PMID: 12711113)
Int J Gen Med. 2021 Dec 10;14:9567-9588. (PMID: 34916838)
J Clin Oncol. 2002 Feb 1;20(3):826-32. (PMID: 11821467)
Stat Med. 2000 Feb 15;19(3):335-51. (PMID: 10649300)
J Clin Epidemiol. 1999 Dec;52(12):1131-6. (PMID: 10580775)
Int J Cancer. 2015 Feb 1;136(3):632-8. (PMID: 24917360)
Lancet Oncol. 2013 Dec;14(13):1262-3. (PMID: 25035875)
Eur J Cancer. 2004 Oct;40(15):2317-22. (PMID: 15454258)
Cancer Lett. 2020 Jan 1;468:82-87. (PMID: 31600530)
Cancer Causes Control. 2010 May;21(5):777-85. (PMID: 20084541)
Natl Cancer Inst Monogr. 1961 Sep;6:101-21. (PMID: 13889176)
PLoS Med. 2022 Aug 25;19(8):e1004064. (PMID: 36006870)
فهرسة مساهمة: Keywords: Epidemiology; Incidence; Lung cancer; Prevalence; Survival; Trends
تواريخ الأحداث: Date Created: 20240223 Latest Revision: 20240224
رمز التحديث: 20240224
مُعرف محوري في PubMed: PMC10882113
DOI: 10.1016/j.lanwpc.2024.101030
PMID: 38389934
قاعدة البيانات: MEDLINE
الوصف
تدمد:2666-6065
DOI:10.1016/j.lanwpc.2024.101030